Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FC-005
- Development stage
- Preclinical
- Lead developer
- FeroptoCure
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FC-005 is an orally available small molecule therapeutic being developed by FeroptoCure in collaboration with a Japanese university. It is designed to induce ferroptosis-mediated synthetic lethality in cancer cells by simultaneously inhibiting the cystine/glutamate antiporter xCT (SLC7A11) and aldehyde dehydrogenase (ALDH). By blocking xCT, the drug depletes intracellular glutathione, while ALDH inhibition prevents the detoxification of lipid peroxides, collectively triggering iron-dependent cell death. Currently in preclinical development, FC-005 targets undisclosed indications, likely within the oncology space.
02
Targets
ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)SLC7A11 (Cystine-Glutamate Antiporter)
Beyond the preview
Go deeper on FC-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FC-005.